Loading...
Market
What will be the market outcome of Soleno's DCCR tablets by end of 2025?
2
Resolution / Starting Odds
Top-selling PWS treatment • 25%
Moderate market success • 25%
Limited market impact • 25%
Withdrawn from market • 25%
Sales reports and market analysis from industry reports
Story
Soleno Therapeutics' Stock Soars 12% to 52-Week High as FDA Backs Prader-Willi Syndrome Drug
Oct 8, 2024, 03:17 PM
Soleno Therapeutics has announced a regulatory update on its DCCR (diazoxide choline) Extended-Release Tablets for the treatment of Prader-Willi Syndrome. The FDA has decided not to require an advisory committee meeting for the drug, indicating a strong outlook for its approval. This decision has positively impacted Soleno Therapeutics' stock, which has increased by 12% to a new 52-week high and by 7.9% pre-market. The company has also received Priority Review for its drug candidate, further supporting the potential for approval. The lack of an advisory committee meeting reduces potential uncertainty, and the market is optimistic about the drug's approval due to the strong data supporting its efficacy and the unmet need for treatments addressing PWS-associated hyperphagia.
View original story
Similar markets
Approved • 25%
Approved with conditions • 25%
Rejected • 25%
Review extended • 25%
Approved • 25%
Not Approved • 25%
Conditional Approval • 25%
Approval Delayed • 25%
Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Request for More Data • 25%
Approval recommended • 25%
Approval not recommended • 25%
No consensus • 25%
Meeting postponed • 25%
Significant Increase (>20%) • 25%
Moderate Increase (10-20%) • 25%
No Significant Change • 25%
Decrease • 25%
Increase >10% • 25%
Increase <=10% • 25%
Decrease <=10% • 25%
Decrease >10% • 25%
Yes • 50%
No • 50%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%